Shots:
- Dymicron received the US FDA’s IDE approval to initiate a pivotal trial of Triadyme-C, a cervical artificial disc, to treat symptomatic cervical disc disease (SCDD) across leading US spine centers starting Q4’25
- The study will compare the safety and effectiveness of Triadyme-C vs. anterior cervical discectomy and fusion (ACDF). The 1EP of the study is defined as NDI score improvement, neurostatus maintenance, and no secondary surgeries
- Triadyme-C features Adymite, a proprietary polycrystalline diamond material engineered to minimize wear debris and replicate spinal motion via tri-lobed design
Ref: PRNewswire | Image: Dymicron| Press Release
Related News:- Taiho Oncology (Part of Taiho Pharmaceutical) Reports the US FDA’s sNDA Acceptance of Inqovi + Venetoclax for Newly Diagnosed AML
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
